In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

TCTMD reported in-depth on the FAVOR III Europe trial, October 30, 2024, at the TCT 2024 meeting. The full manuscript was subsequently published in EuroIntervention in January 2025. The published ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.